Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings by SCHUETZ, P. et al.
Predicting mortality with pneumonia severity scores:
importance of model recalibration to local settings
P. SCHUETZ 1,2*#, M. KOLLER 2#, M. CHRIST-CRAIN 1, E. STEYERBERG3,
D. STOLZ 4, C. MU¨LLER1, H. C. BUCHER 2, R. BINGISSER 1, M. TAMM4
AND B. MU¨LLER 1
1 University Hospital Basel, Department of Internal Medicine, Basel, Switzerland
2 Basel Institute for Clinical Epidemiology, Basel, Switzerland
3 Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
4 Clinic of Pneumology and Pulmonary Cell Research, University Hospital Basel, Switzerland
(Accepted 31 January 2008; ﬁrst published online 27 February 2008)
SUMMARY
In patients with community-acquired pneumonia (CAP) prediction rules based on individual
predicted mortalities are frequently used to support decision-making for in-patient vs. outpatient
management. We studied the accuracy and the need for recalibration of three risk prediction
scores in a tertiary-care University hospital emergency-department setting in Switzerland.
We pooled data from patients with CAP enrolled in two randomized controlled trials. We
compared expected mortality from the original pneumonia severity index (PSI), CURB65 and
CRB65 scores against observed mortality (calibration) and recalibrated the scores by ﬁtting the
intercept a and the calibration slope b from our calibration model. Each of the original models
underestimated the observed 30-day mortality of 11%, in 371 patients admitted to the emergency
department with CAP (8.4%, 5.5% and 5.0% for the PSI, CURB65 and CRB65 scores,
respectively). In particular, we observed a relevant mortality within the low risk classes of the
original models (2.6%, 5.3%, and 3.7% for PSI classes I–III, CURB65 classes 0–1, and CRB65
class 0, respectively). Recalibration of the original risk models corrected the miscalibration. After
recalibration, however, only PSI class I was sensitive enough to identify patients with a low risk
(i.e.<1%) for mortality suitable for outpatient management. In our tertiary-care setting with
mostly referred in-patients, CAP risk scores substantially underestimated observed mortalities
misclassifying patients with relevant risks of death suitable for outpatient management. Prior to
the implementation of CAP risk scores in the clinical setting, the need for recalibration and the
accuracy of low-risk re-classiﬁcation should be studied in order to adhere with discharge
guidelines and guarantee patients’ safety.
INTRODUCTION
Community-acquired pneumonia (CAP) is the lead-
ing cause of death from infectious diseases in western
countries and health expenditures in particular for
in-patient management of patients with CAP are
substantial [1, 2]. Accurate assessment of disease sev-
erity, risk stratiﬁcation and prediction of outcome
are, therefore, prerequisites for the safe identiﬁcation
of patients with CAP at low risk of complications
and thus suitable for outpatient management. Several
international organizations have developed predic-
tion rules and adopted guidelines to stratify patients
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with CAP based on predicted mortalities for the
identiﬁcation of patients with CAP that may be
managed in an outpatient setting in order to optimize
hospital referral and lower hospital admission rates
[3, 4]. The pneumonia severity index (PSI) is a widely
propagated scoring system in North America that
assesses the risk of death in a two-step algorithm [5].
The CURB65# score is the modiﬁed version of the
British Thoracic Society (BTS) assessment tool which
is based on only ﬁve predictors and used in Europe
[6, 7]. The CRB65 score has been put forward as a
useful substitute for the CURB65 as it does not rely
on laboratory measurements and still shows accept-
able discriminatory ability [7, 8].
Prior to the implementation of a statistically de-
rived prediction score, an external validation within
locally generated data should be conducted [9]. With
only few exceptions [10], external validation studies
of pneumonia severity scores have focused on dis-
criminative properties, i.e. the ability of the score to
distinguish patients with CAP and fatal outcome
from those surviving [10–17]. Despite good discrimi-
natory abilities, most validation studies found higher
mortality rates of patients with PSI class III and
CURB65 class 1 than was reported in the original
studies. Because management strategies of patients
with CAP depend on cut-oﬀ values of absolute
predicted mortalities, it is essential that predicted
risks agree with observed risks in the population
in question. This is referred to as calibration. Mis-
calibration may lead to inadequate discharge of
patients with high mortality (risk underestimation) or
inadequate hospitalization of low-risk patients (risk
overestimation).
The aim of our study was to validate the calibration
and assess the need for recalibration of three well
established pneumonia severity prediction scores in a
tertiary-care setting in Switzerland.
METHODS
Study sample
For this analysis we pooled data from two random-
ized controlled studies enrolling patients with lower
respiratory tract infections presenting to the emerg-
ency department (ED) of the University Hospital
of Basel, Switzerland. The design of the two trials
was similar and a complete description has been
reported in detail elsewhere [18, 19]. In brief, the
ﬁrst trial included 243 consecutive patients with
clinically suspected lower respiratory tract infections
including acute and exacerbation of chronic bron-
chitis, and CAP, admitted from December 2002 until
April 2003. The second trial included 302 patients
with radiologically conﬁrmed CAP admitted between
November 2003 and February 2005. In both trials,
patients were randomly assigned to procalcitonin-
guided antibiotic therapy (n=124 or n=151, respect-
ively) or to standard treatment according to guide-
lines (n=119 or n=151, respectively) [3, 4]. The aim
of both trials was to study whether procalcitonin-
guided antibiotic treatment can reduce the amount of
antibiotic consumption and 30-day mortality was
monitored as a secondary endpoint. The ﬁrst trial
measured procalcitonin only on admission, whilst in
the second trial follow-up procalcitoninmeasurements
were performed. For the purpose of this analysis, only
patients with a deﬁnite diagnosis of CAP were con-
sidered. CAP was deﬁned as the presence of a new
inﬁltrate on chest radiograph accompanied by one,
or several, acquired acute respiratory symptoms and
signs such as cough, sputum production, dyspnoea,
fever >38.0 xC, auscultatory ﬁndings of abnormal
breath sounds and rales, leucocytosis >1010 cells/l,
or leucopenia <4r109 cells/l [3]. In-patient or out-
patient management of patients was not an exclusion
criteria for either trial. Patients with other lower
respiratory tract infections than CAP, including
bronchitis or exacerbation of chronic obstructive
pulmonary disease and asthma were not considered.
Furthermore, patients with cystic ﬁbrosis, active pul-
monary tuberculosis, hospital-acquired pneumonia
and severe immunosuppression (patients infected with
human immunodeﬁciency virus infection and a CD4
count <350r109/l, patients on immunosuppressive
therapy after solid organ transplantation and neu-
tropenic patients with a present neutrophil count
<500r109/l and patients under chemotherapy with
neutrophils 500–1000r109/l with an expected de-
crease to values <500r109/l) were not eligible for
trial inclusion.
Patients were examined on admission to the ED by
a medical resident supervised by a board-certiﬁed
specialist in internal medicine. Baseline assessment
included collection of clinical data and vital signs,
comorbid conditions, and routine blood tests. All
study forms were completed contemporaneously.
# CURB65, Confusion, Urea >7 mmol/l, Respiratory rate >30/
min, low Blood pressure (systolic <90 mmHg or diastolic
<60 mmHg). CRB65, the same as CURB65, but does not include
urea.
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Since neither of the trials showed a signiﬁcant dif-
ference between the intervention arm and the control
arm regarding all-cause mortality (pooled OR 0.78,
95% CI 0.41–1.50, P=0.46), treatment assignment
was not considered any further in this analysis. In
addition, the coeﬃcients of the calibration models
did not diﬀer between the intervention group and
the control group of the study population for any of
the three models assessed.
Both trials had been approved by the local Ethical
Committees and registered in the Current Controlled
Trials Database (ISRCTN04176397) ; all patients
gave written informed consent.
Severity assessment and outcome
The PSI, CURB65 and CRB65 scores were calculated
in all patients on the basis of the patients’ unique set
of prognostic indicators. Identical to the outcome
deﬁnition of the original models [5, 7, 8], we used
30-day mortality as outcome for our validation study,
which was collected in both trials as part of the trial
safety monitoring.
Statistical analysis
We performed external validation of the three original
models by assessing calibration and discrimination.
We ﬁrst studied calibration in a descriptive way by
tabulating and plotting observed mortality across
classes of predicted mortality as given with the orig-
inal models [5, 7]. We then studied calibration in the
context of a simple calibration model ﬁtting the logit
of the predicted mortality from the original models
against the binary outcome (death or alive at 30 days)
from our study population using logistic regression
[20, 21]. This calibration model has the advantage of
eﬃciency since it uses only two free parameters : an
intercept a and a calibration slope b. In the ideal case
of perfect validity, a=0 and b=1. The parameters
can be tested with ANOVA or Wald statistics. If a or
b signiﬁcantly deviate from the ideal case, then there is
evidence of miscalibration and model recalibration
should be performed [20, 21]. The recalibrated risk
can be calculated as a^+b^*log (prob=(1xprob)) with
probabilities (prob) originating from the original
model and the coeﬃcients originating from the cali-
bration model (see Appendix). We did not compare
observed mortality with predicted mortality within
risk classes per model for all three models due to the
low eﬃciency of this approach. For each model with
ﬁve classes this approach would result in ﬁve one-
sample proportion tests (the random observed mor-
tality against the ﬁxed predicted mortality). In fact we
would need to spend 5 degrees of freedom (D.F.) per
model instead of 2 D.F. with the calibration model
approach and additionally we had the problem of
multiple comparisons [20].
Discrimination refers to the ability of the model to
assign a higher predicted mortality to all patients with
an outcome (30-day mortality) compared to patients
without an outcome. We assessed discrimination
using the c statistic which is equal to the area under
the receiver-operating characteristics (ROC) curve.
Moreover, we used the Brier score as an overall
measure of model performance [22].
We used R version 2.3.1 [23] and the Design library
[24] for statistical analyses.
RESULTS
Baseline characteristics
Between December 2002 and February 2005, a total
of 483 (96 in the ﬁrst and 387 in the second trial)
consecutive patients with an initial diagnosis of
CAP were screened for eligibility (Fig. 1). CAP
was radiologically conﬁrmed in 373 (87 and 286)
patients who are included in this analysis. In total, 110
patients were excluded because of the use of im-
munosuppressive drugs (n=46), hospital-acquired
pneumonia (n=17), non-CAP diagnosis (n=16),
tuberculosis (n=3), cystic ﬁbrosis (n=1), death
before inclusion (n=2) or due to refusal of informed
consent (n=25). The median age of the patients was
483 Patients presenting with a provisional
diagnosis of CAP to the emergency room
373 Patients included in the two studies
110 Not included
46 Immunosupression
17 Hospital-acquired pneumonia
16 Non-CAP diagnosis
3 Tuberculosis
1 Cystic fibrosis
2 Death before inclusion
25 No informed consent
356 In-patients 17 Outpatients
Fig. 1. Flow chart of all 373 patients included in this study.
CAP, Community-acquired pneumonia.
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73 years [inter-quartile range (IQR) 59–82 years],
84 patients (23%) were smokers with a median of 40
pack years (IQR 20–50) and 90 (24%) of the patients
had an underlying chronic obstructive lung disease.
Forty-nine percent of the patients (n=184) were ran-
domized to receive antibiotic treatment according
to procalcitonin guidance and 51% patients (n=189)
were allocated to the control group. The majority of
the patients (95.4%) were treated as in-patients with
a median length of hospital stay of 11 days (IQR 6–17
days). Outpatients were predominantly in low-risk
classes of PSI score (53% in class I, 29% in class II)
and of CURB65 and CRB65 scores (76% each in
class 0). Baseline characteristics of our study popu-
lation are summarized in Table 1. For comparison,
the characteristics of the study populations where
the original models were developed are also given
in Table 1 [5, 7].
Calibration of the three diﬀerent rules
Overall, 41/373 patients died (4/96 and 37/373) and
the overall mortality was 11%. The proportion of
intensive care unit (ICU) admission was 8% (8/96) in
the ﬁrst and 10% (37/373) in the second study.
Table 2 and the calibration plots in Figure 2 illus-
trate predicted mortality from the original models
against observed mortality within classes of predicted
mortality. Compared to the observed mortality of
11%, the predicted average 30-day mortality was
underestimated with each of the original models
(8.4% for PSI, 5.5% for CURB65, 5.0% for CRB65,
respectively). Importantly, within the low-risk classes
of the original models we observed relevant mor-
talities of 2.6%, 5.3%, and 3.7% (PSI classes I–III,
CURB65 classes 0–1, and CRB class 0, respectively)
(Table 2). Low-risk predictions from each of the
original models were therefore on average four times
underrated compared to the observed mortalities
within low-risk classes. The risk estimates in the high-
risk classes were more accurate for all scores. The PSI
score, but not the CURB65 and CRB65 scores slightly
overestimated the risk of death in the highest risk class
(Fig. 2). The four patients misclassiﬁed in the PSI and
the three patients misclassiﬁed in the CURB65 score
were younger [median age 67 years (IQR 62–75) and
59 years (IQR 57–61)] compared to correctly classiﬁed
non-survivors [median age 79 years (IQR 70–86)].
Calibration models showed signiﬁcant miscalibra-
tion of the b slope for all scores (P<0.001 each)
underlining the necessity of recalibration (see
Appendix). Calibration plots in Figure 2 show the
impact of recalibration of the original models : the re-
calibrated mortalities are in good agreement with
the observed 30-day mortality and therefore show
good calibration for each model. Details on the
calculation of recalibrated mortalities are given in a
worked example in the Appendix. In the low-risk
classes, recalibration corrected risk estimation for
the PSI score (classes I–III) from 0.5% to 2.7%,
for the CURB65 score (classes 0 and 1) from 1.2%
to 5% and for the CRB65 score (class 0) from 0.9%
to 3.5%, compared to the observedmortality of 2.5%,
5.3% and 3.7% in the corresponding risk category
of each model. Within our tertiary-care setting of
high-risk patients, only the recalibrated PSI was an
adequate tool for the identiﬁcation of low-risk patients
with a predicted mortality in the low range of 1%.
Patients in the lowest risk classes of recalibrated
CURB65 and CRB65 scores still had relevant mor-
tality rates of 3.6% and 3.5% (Table 3) respectively.
Only the recalibrated PSI class I score was therefore
adequate for classifying patients as low risk in the
range of 1%. Table 3 shows the identiﬁcation of low-
risk patients according to the original and the recali-
brated PSI score. The original model classiﬁed 162
patients (43%) as low risk (classes I–III) with an ob-
served mortality of 2.5%. The recalibrated PSI class I
identiﬁed 41 patients (11%) as low risk with an ob-
served mortality of 0%. Accordingly, the sensitivities
and speciﬁcities of the original PSI risk model were
90.2% and 47.3%, and 100% and 12.3% for the
recalibrated PSI score, respectively.
Discriminatory ability
We performed ROC analysis to assess the discrimi-
natory ability of the three prognostic scores (Fig. 3).
The PSI score had an area under the curve (AUC) of
0.72 (95% CI 0.65–0.78). The respective values for
CURB65 and CRB65 scores were 0.69 (95% CI
0.61–0.77) and 0.66 (95% CI 0.58–0.73). The corre-
sponding Brier score was 0.094, 0.096 and 0.098 for
PSI, CURB65 and CRB65 indicating the lowest pre-
diction error for the PSI score. Recalibration did not
numerically aﬀect the discriminatory ability of the
models.
DISCUSSION
We performed an external validation study of three
well established mortality prediction rules in 373
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Table 1. Baseline characteristics of the study population
Baseline characteristics
Study cohort
(n=373)
PSI cohort
(n=2287)
CURB65 cohort
(n=1068)
Demographics
Age, years*, 73 (59–82) 69 (17–100)
<0 yr (%)# 16.7 42.7 18.8
Male sex (%) 60.1 50.0 51.5
Nursing home resident (%) 8.5 0
Coexisting illnesses (%)
Heart disease 42.4 11.1 18
Cerebrovascular disease 5.4 9.2 9
Renal dysfunction 27.1 6.7
Liver disease 10.5 1.4 1
Chronic lung disease 24.1 35
Neoplastic disease 14.2 5.8
Clinical signs
Altered mental status 8.3 10.4 11.7
Rales (%) 72.3
Systolic blood pressure (mmHg)* 130 (112–142)
<90 mmHg (%)# 3.2 2.1 18.6
Pulse rate (bpm)* 95 (81–110)
>124 /min (%)# 6.4 8.7 8.1
Respiratory rate 22 (20–28)
>29/min (%)# 16.9 13.3 25.9
Temperature (xC)* 38.4 (37.6–39.2)
<35 xC,>39.9 xC (%)# 7.8 1.6
Pleural eﬀusion (%) 17.2 8.9 10.9
Laboratory parameters
Arterial pH 7.43 (7.42–7.44)
<7.35 (%)# 4.0 3.7
Urea (mmol/l) (%) 6.8 (4.9–11.5)
>7 mmol/l# 47.7 33.5
>10.9 mmol/l# 27.3 14.3
Sodium (mmol/l) 135.6 (133.0–138.0)
<130 mmol/l (%)# 11.0 3.9
Glucose (mmol/l) 6.6 (5.6–8.2)
>13.9 mmol/l (%)# 4.6 4.2
Haematocrit (%) 38 (35–40)
<30% (%)# 4.8 6.3
PaO2 (mmHg) 60.7 (58.5–63)
<60 mmHg (%)# 27.3 20.6 25.0
Severity assessment (%)#
PSI class I 11.0 33.8 12
PSI class II 13.4 20.9 20
PSI class III 19.0 14.3 21
PSI class IV 40.2 21.3 33
PSI class V 16.4 9.9 13
Outcome parameters (%)#
ICU admission 9.0 9.2 4.0
Outpatient management 4.6 41.3
Mortality 11.0 5.2 9.0
PSI, Pneumonia severity index; ICU, intensive care unit.
* Values are expressed as median and interquartile range (IQR).
# Because of rounding, percentages may not sum to 100.
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patients with CAP admitted to a tertiary-care centre
in Switzerland. There was acceptable discriminatory
performance but all scores markedly underestimated
the mortality, particularly in the low-risk classes. This
leads to misclassiﬁcation of patients with a substantial
mortality in the low-risk classes. As guidelines [3, 4]
recommend outpatient management for low-risk
patients, misclassiﬁcation may result in inadequate
discharge of patients with a considerable risk of death
and potential legal consequences. Recalibration of the
risk models corrected the miscalibration of predicted
mortalities of all models under investigation. Of the
recalibrated models, only the PSI was sensitive
enough to accurately identify low-risk patients suitable
for outpatient management.
Three diﬀerent prediction rules, namely the PSI,
CURB65 and CRB65 scores, have been proposed
and extensively validated for risk stratiﬁcation in
CAP [3–6]. All three rules are originally designed
to identify patients who are at low risk of death
and who may hence qualify for outpatient manage-
ment. Algorithms from statistical prediction models
reﬂect the risk proﬁle of patients embedded in
a certain health-care setting where the original
model was derived. Consequently, when transporting
these rules to diﬀerent settings at diﬀerent times,
validation and adaptation, if needed, is recommended
[20, 21].
The original PSI, CURB65 and CRB65 classiﬁed
43%, 55% and 30% of the patients as low risk with a
presumed mortality in the range of 1%. If the original
models were well calibrated in our data, the observed
mortalities in the low-risk classes would not have ex-
ceeded 1%. However, we observed mortalities of
2.5%, 5.3% and 3.6% indicating the need to recali-
brate the models in our tertiary-care setting. Using a
basic recalibration approach, the miscalibration of
each model (Fig. 2) and the resulting misclassiﬁcation
of patients was corrected. Nevertheless, with mor-
tality rates of 3.5% each in the lowest risk classes, the
CURB65 and CRB65 scores were too insensitive to
identify subjects with low mortality rates in the range
of 1%. Consequently, the CURB65 and CRB65
may help to identify patients at high risk, but their
ability to recognize low-risk patients is limited. Unlike
the CURB65 and the CRB65, the recalibrated
PSI score showed an adequate performance in the
low-risk range and was able to correctly identify 11%
of the patients with a mortality of 1%. Only class
I of the recalibrated PSI score can therefore be
used to identify patients who qualify for outpatient
management.
Table 2. Observed and predicted mortality in patients with community-acquired pneumonia (n=373)
Risk class
Observed Original model Recalibrated model
No. of patients
per class (%)
Death (%)
(n=41)
Expected no.
of deaths
Expected
mortality (%)
Expected no.
of deaths
Expected
mortality (%)
PSI
I 41 (11.0) 0 (0) 0.04 0.1 0.5 1.1
II 50 (13.4) 1 (2.0) 0.3 0.6 1.6 3.1
III 71 (19.0) 3 (4.2) 0.6 0.9 2.8 3.9
IV 150 (40.2) 24 (16.0) 14.0 9.3 20.9 13.9
V 61 (16.4) 13 (21.3) 16.5 27.0 15.4 25.2
CURB65
0 87 (23.3) 3 (3.4) 0.5 0.6 3.1 3.6
1 119 (31.9) 8 (6.7) 2.0 1.7 7.7 6.5
2 131 (35.1) 21 (16.0) 11.8 9.0 21.6 16.5
3 33 (8.9) 8 (24.2) 5.3 16.1 7.5 22.7
4/5 3 (0.8) 1 (33.3) 1.1 35.1 1.1 35.6
CRB65
0 109 (29.2) 4 (3.7) 1.0 0.9 3.8 3.5
1 219 (58.7) 26 (11.9) 11.4 5.2 27.2 12.4
2 40 (10.7) 9 (22.5) 4.8 12.0 8.5 21.3
3 5 (1.3) 2 (40.0) 1.6 32.4 2.0 40.8
4 0 (0) 0.0 21.0
PSI, Pneumonia severity index; CURB, Confusion, Urea >7 mmol/l, Respiratory rate >30/min, low Blood pressure
(systolic<90 mmHg or diastolic<60 mmHg) ; CRB65, the same as CURB65, but does not include urea.
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Prior validation studies have prospectively evalu-
ated severity scores in diﬀerent clinical settings and
reported high mortality rates particularly in patients
of PSI class III or above and CURB65 class 1 or
above [10–17]. These studies, however, focused
mainly on the overall discriminatory ability of the
prediction rules with varying results as expressed by
diﬀerences in the area under the ROC curves. The
present study extends these ﬁndings showing that
an apparently adequate discriminatory model may
mislead clinical decisions because of model mis-
calibration in a particular clinical setting. Import-
antly, the ROC of a prediction model is numerically
not aﬀected by miscalibration because miscalibration
aﬀects the magnitude of the predicted overall risk but
not the ranking among the individual patients
according to their predicted risks. Validation of both,
calibration and discrimination, is thus crucial before a
model which is derived at a diﬀerent time and place is
implemented in a clinical setting.
The present study does not per se question the
utility of these tools, but underlines the importance of
adapting these tools to local settings. The study em-
phasizes the importance of validation by calibration
and of recalibration in the case of signiﬁcant mis-
calibration. Although our study population diﬀers
from the original derivation population, the assess-
ment of model calibration in the high-risk setting is
from a pragmatic point of view of interest. CAP
guidelines recommend the use of CAP risk scores, also
in EDs, but do not specify the setting where the scores
are indicated or not. In a high-risk population, as
found in our study with a high proportion of referred
polymorbid patients, risk scores may underestimate
mortality risks, while in a low-risk setting (e.g. pri-
mary care) risk predictions may be inadequately high.
Importantly, misclassiﬁed patients were found to be
younger compared to correctly classiﬁed patients. As
age is the strongest predictor in the risk scores, the
risk of younger people may particularly be under-
estimated in the high-risk setting.
When evaluating a model for risk stratiﬁcation, one
should start using pre-existing knowledge and, if avail-
able, validate and update an existing model within the
setting in question instead of building a new model
from scratch with all the drawbacks of overﬁtting and
lack of reproducibility [25]. Recalibration of existing
models is attractive because of the stability which is
related to the fact that only two parameters (intercept
and calibration slope) are estimated [20] (see Methods
section). Directly using the observed risk pertaining to
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Fig. 2. Agreement between predicted and observed 30-day
mortality (calibration) for three pneumonia severity pre-
diction rules (a) PSI, (b) CURB65 and (c) CRB65. Observed
mortality is plotted according to classes of predicted
risk for each prediction rule separately. The solid line of
identity represents perfect calibration of predicted risk
within new patients. Correction of miscalibration ( ) after
recalibration (1).
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a certain risk class is hampered through the potential
imprecision due to the small number of observations
within a certain class of predicted risk (Table 2). The
recalibration approach is preferable since it is eﬃcient
and uses only two parameters which is of particular
relevance in small samples as exempliﬁed in our pre-
vious study [20].
This study included a typical spectrum of CAP
patients from a university hospital in Switzerland.
Our study population was diﬀerent to the original
study population of the PSI score in terms of age,
comorbidities (e.g. renal failure, heart disease and
neoplastic disease) and laboratory ﬁndings. As a study
from a European tertiary-care centre, most patients
were referred and selected from family physicians
requesting in-patient management. Accordingly,
patients had more severe pneumonia as assessed by
the PSI score, the rate of outpatient management
was low and mortality and rate of ICU admission was
higher than in the original studies. However, we con-
sider the population from this study as representative
for the European tertiary-care setting, especially for
Western Europe. In this study, the 5% of patients
treated as outpatients were predominantly in the
lowest risk classes of PSI, CURB65 and CRB65
scores. In comparison with 11% of low-risk patients
according to the recalibrated PSI score, the manage-
ment of CAP patients was reasonable after all. As
outlined by guidelines, mortality prediction rules
should be used to support but not replace physician
decision-making about outpatient or in-patient
management [3, 4]. Patients may have rare medical
conditions, and patients designated as ‘ low risk’ may
have medical and psychosocial contraindications to
outpatient care. Particularly, the ability to maintain
oral intake, cognitive impairment, and ability to carry
out activities of daily living need to be considered.
Thus, determination of the initial site of care still
remains an ‘art of medicine’ decision that, yet, may
not be replaced by prediction rules [3].
Some limitations should be considered in the dis-
cussion of our results. First, the number of outcome
events to perform an external validation study was
rather low [26]. Second, we validated the severity
scores in two trials with prospective follow-up where
the issues of patient selection and representativeness
of the population need to be addressed. However,
the two trials consecutively included all patients
with CAP, irrespective of in-patient or outpatient
management. The study inclusion criteria corre-
sponded to the criteria used in the original studies
and to the criteria of CAP guidelines. In the original
studies, the main reason for exclusion was non-CAP
Table 3. Accuracy of the original and the recalibrated PSI score to
identify patients at low risk of death
PSI original
(classes I–III*)
PSI recalibrated
(class I*)
Number of patients assigned
to low-risk class#
43% (162/373) 11% (41/373)
Mortality within low-risk class 2.5% (4/162) 0% (0/41)
Sensitivity 90.2% 100.0%
Speciﬁcity 47.3% 12.3%
PSI, Pneumonia severity index.
* Classes I–III of the original PSI score correspond to a low mortality of f1%.
After recalibration of the original model, only class I corresponds to a mortality of
f1% and therefore classiﬁes patients as suitable for outpatient management.
# Mortalityf1%.
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AUC: 0·66 (95% CI 0·58–0·73)
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Fig. 3. Receiver-operating characteristics analysis for
30-day mortality prediction with three original pneumonia
severity prediction rules (PSI, CURB65 and CRB65) in 373
patients with CAP.
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diagnosis and only a minority of patients was ex-
cluded because of severe contraindications such as
immunosuppression or tuberculosis. It is reasonable
to believe that the existing severity scores would
rather underestimate the risk for rare conditions, and
thus, an error because of unrepresentativeness would
at least be conservative. Third, our analysis is based
on predicted risks categorized in ﬁve risk classes, as
issued by the original models. Preferably, we would
have performed validation of the models based on a
patient’s individual risk using the coeﬃcients of the
original risk functions and each patient’s risk
proﬁle. To the best of our knowledge the original
risk functions are not published. With the full model
to hand, a more diﬀerentiated picture of the per-
formance in new data might have been possible.
In conclusion, without recalibration the original
PSI, CURB65 andCRB65 scoresmisclassiﬁed patients
with a relevant mortality as low risk in our Western
European tertiary-care setting. Recalibration cor-
rected miscalibration in each model, but only the PSI
score was sensitive enough to truly identify patients at
low risk. Based on this study, we advocate using the
PSI prediction rule for severity assessment and con-
sideration of outpatient management for patients
with a PSI risk class I. Nevertheless, even recalibrated
estimates need ongoing prospective validation and
updating.
APPENDIX
Coeﬃcients of the calibration models for the three
validated risk scores
PSI CURB65 CRB65
Intercept a^ x0.5167
(P=0.13)
x0.2321
(P=0.61)
0.1766
(P=0.77)
Calibration
slope b^
0.5734
(P<0.001)
0.6004
(P<0.001)
0.7426
(P<0.001)
Example
Recalibration of the morality estimate from the orig-
inal model in a patient with PSI class III :
Recalibrated mortality
=1=(1+ exp (x(a^+b^*( log (riskoriginal=
(1xriskoriginal))))))
0039=1=(1+ exp (x(x05167+05734*( log (09=
(1x09)))))):
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